Rapamycin inhibition of the Akt/mTOR pathway blocks select stages of VEGF-A164-driven angiogenesis, in part by blocking S6Kinase. - Wikidata - awgldk - TriplyDB

Rapamycin inhibition of the Akt/mTOR pathway blocks select stages of VEGF-A164-driven angiogenesis, in part by blocking S6Kinase.

Rapamycin inhibition of the Akt/mTOR pathway blocks select stages of VEGF-A164-driven angiogenesis, in part by blocking S6Kinase.

http://www.wikidata.org/entity/Q37374986

about

Potential use of rapamycin in HIV infection Novel nervous and multi-system regenerative therapeutic strategies for diabetes mellitus with mTOR Endothelial Cell mTOR Complex-2 Regulates Sprouting Angiogenesis Clinical activity and safety of combination therapy with temsirolimus and bevacizumab for advanced melanoma: a phase II trial (CTEP 7190/Mel47)Hypoxia induces permeability and giant cell responses of Andes virus-infected pulmonary endothelial cells by activating the mTOR-S6K signaling pathway.Hantavirus interferon regulation and virulence determinants Virus interactions with endothelial cell receptors: implications for viral pathogenesis.Increased Akt-mTOR signaling in lung epithelium is associated with respiratory distress syndrome in mice Identification and functional analysis of endothelial tip cell-enriched genes Regulation of endothelial cell proliferation and vascular assembly through distinct mTORC2 signaling pathways.Heterogeneity of the tumor vasculature.Anti-VEGF/VEGFR therapy for cancer: reassessing the target.Mammalian target of rapamycin signaling in diabetic cardiovascular disease N-carbamylglutamate enhances pregnancy outcome in rats through activation of the PI3K/PKB/mTOR signaling pathway.Andes virus infection of lymphatic endothelial cells causes giant cell and enhanced permeability responses that are rapamycin and vascular endothelial growth factor C sensitive.Insulin-like growth factor binding protein-3 suppresses vascular endothelial growth factor expression and tumor angiogenesis in head and neck squamous cell carcinoma.Rapamycin Protects from Type-I Peritoneal Membrane Failure Inhibiting the Angiogenesis, Lymphangiogenesis, and Endo-MT.Heterogeneity of the tumor vasculature: the need for new tumor blood vessel type-specific targets LY2228820 dimesylate, a selective inhibitor of p38 mitogen-activated protein kinase, reduces angiogenic endothelial cord formation in vitro and in vivo.Endothelial cell-fatty acid binding protein 4 promotes angiogenesis: role of stem cell factor/c-kit pathway.Modulatory effect of curcumin on survival of irradiated human intestinal microvascular endothelial cells: role of Akt/mTOR and NF-{kappa}B.Adventitial nab-rapamycin injection reduces porcine femoral artery luminal stenosis induced by balloon angioplasty via inhibition of medial proliferation and adventitial inflammation.Hsp90β promoted endothelial cell-dependent tumor angiogenesis in hepatocellular carcinoma.Prospects for mTOR inhibitor use in patients with polycystic kidney disease and hamartomatous diseases.Selectively starving cancer cells through dietary manipulation: methods and clinical implications.Reduced VEGF production, angiogenesis, and vascular regrowth contribute to the antitumor properties of dual mTORC1/mTORC2 inhibitors.Role of vascular and lymphatic endothelial cells in hantavirus pulmonary syndrome suggests targeted therapeutic approaches.The Role of the Endothelium in HPS Pathogenesis and Potential Therapeutic Approaches.Chemoprevention of age-related macular regeneration (AMD) with rapamycin.mTOR co-targeting strategies for head and neck cancer therapy R-Ras-Akt axis induces endothelial lumenogenesis and regulates the patency of regenerating vasculature.Glucocorticoid effects on angiogenesis are associated with mTOR pathway activity.Hypoxia-induced autophagy in endothelial cells: a double-edged sword in the progression of infantile haemangioma?Treatment of voluminous and complicated superficial slow-flow vascular malformations with sirolimus (PERFORMUS): protocol for a multicenter phase 2 trial with a randomized observational-phase design.

P2860

Q24606795-3763824D-CBF1-4267-9522-26A8D2715B97 Q26749047-5BB166BE-7ECE-405B-A4E5-2DC6E0BB0D39 Q28547399-AD2CC84C-D323-4A74-AB57-36A1B8573B8A Q30412106-757F9954-91AE-435A-8B78-A9379A1E8949 Q33410566-DCB71820-53FC-438A-BFE0-D445D40FD7B2 Q33758371-B5D8AB22-0F58-44E0-9E33-D70D071A4DE9 Q34388874-FCA6C393-C96A-4954-87CA-C25CCC343018 Q34742261-08174BBB-B9B0-4409-AF2F-98396928E7D1 Q35040504-2D32F92A-A245-430F-8F03-82006984994B Q35165191-64B16D4B-0A63-4ECF-881D-957291F3920A Q35752502-8BD2C8C9-B377-4B66-A037-844E43B567F9 Q35910772-8D5B64CF-2F3F-4AA1-BB16-B39A86A284B9 Q36100715-10098157-C819-4392-A468-CB5A247D2167 Q36123618-CCF1AAF1-B923-4571-9204-695C04E11CE0 Q36171949-94560C2B-F5AF-4DE1-83B8-6168C23076CF Q36300954-7F6736D1-1EF1-4C7E-81AE-713EBBC9DD1E Q36356537-2297400A-1779-493A-9DFB-53FC68C0F7EC Q36357152-77871318-D7F7-457E-BCC1-5A238F74C0B3 Q36647424-E7B25C0F-C44D-426B-935A-50F6037A3B03 Q36664510-3A4C2365-E7B7-420A-AEA1-91FDE6707729 Q37174984-739EE345-0F86-4880-A071-C589843B8A05 Q37463102-7DE8A659-EBD7-443D-A584-9E07C01AB71D Q37731561-7188D78F-CB2C-47F1-8484-B79AF2BE297A Q37760379-62A9C16F-BD95-4740-A67B-C9AA637CEB86 Q38120308-5C0D61C7-A08A-4F15-90AC-D5F44B7A2FCA Q39583739-F67AE09D-34ED-48FF-B206-D2D91ECC338B Q41814495-7FA61EA2-55C6-47D3-8174-D0058C230B79 Q41986585-DA118F37-243E-4D8E-A0C3-564A7E094B57 Q42257672-21C8BC22-583C-44B3-B5A2-ACF2EB5723A4 Q42363764-0C63DB86-B514-4F98-87B5-3E8E67A9A9D0 Q47156326-49224E89-2F3B-429F-8C19-7F240CB1E897 Q50525967-C789F841-7CE0-4BB3-8983-06B44C652575 Q54450000-E374C3D4-E274-403A-9182-A7BE47F4FAFF Q55435436-A1933C82-F447-4969-A4CC-C02ED8130213

P2860

Rapamycin inhibition of the Akt/mTOR pathway blocks select stages of VEGF-A164-driven angiogenesis, in part by blocking S6Kinase.

http://www.wikidata.org/entity/Q37374986

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 14 May 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Rapamycin inhibition of the Ak ...... in part by blocking S6Kinase.

@en

Rapamycin inhibition of the Ak ...... in part by blocking S6Kinase.

@nl

type

label

Rapamycin inhibition of the Ak ...... in part by blocking S6Kinase.

@en

Rapamycin inhibition of the Ak ...... in part by blocking S6Kinase.

@nl

prefLabel

Rapamycin inhibition of the Ak ...... in part by blocking S6Kinase.

@en

Rapamycin inhibition of the Ak ...... in part by blocking S6Kinase.

@nl

P1433

Q37374986-F5B90A0B-2B88-4A99-8F26-EBA8915972F1

P1476

Q37374986-EF5D4883-430E-48D3-A8B6-EADA9DC2F844

P2093

Q37374986-3B4D773F-D170-4416-BEFB-FC55634DD0CB

Q37374986-64FBF693-0B56-442C-B319-A92577B55E19

Q37374986-76F81307-A8A5-4249-B557-50A4B6F52150

Q37374986-8A3FE52B-884F-4E9F-9DF8-E72F62930484

Q37374986-A35BDBF8-291E-4947-A69F-250DC767AF92

Q37374986-F88B7589-8496-4C65-A032-D12A396A0085

P2860

Q37374986-0915612F-85D7-47E3-ABEE-BF0F647E628F

Q37374986-0DF5E3FB-1149-4772-88D2-604EEA74B440

Q37374986-288E128C-BCC5-4030-9949-6BCA6718FF79

Q37374986-2946A0BE-6A25-4AFD-B278-C524701E8B8C

Q37374986-2BE3C809-C4EA-48FB-80D2-401F7C86A961

Q37374986-370D1013-5C21-4F2D-919A-0D1EA1FCDFA4

Q37374986-48C2128C-C32D-4E17-B593-CE04A691BE43

Q37374986-55042032-74D6-4E31-8B0B-DD71499CD224

Q37374986-56E44DA3-9861-4830-9F2B-F9C1BA0F5AF6

Q37374986-57E04518-28CA-4C65-A82E-B93EBF242DF6

P304

Q37374986-BA2A28B4-06FC-43BC-BA3F-5617BDDBA399

P31

Q37374986-C03C3F4F-DE42-47BD-B34F-8D1A5322482F

P356

Q37374986-E3DACE58-B82B-477D-8BDC-157940594354

P407

Q37374986-3EF9BF0E-5FE7-45A8-97B4-4A023E08038C

P433

Q37374986-3140D2C7-FEC4-4F6C-AFBC-331E8D9C1D79

P478

Q37374986-C0B882A1-9B82-40E5-8338-1D1F7A695EB3

P577

Q37374986-D268F196-CCA6-4061-9FF7-BE868B6A21CA

P698

Q37374986-482EC614-9712-4994-8FC9-5B603B11308E

P932

Q37374986-34BB4901-714A-466C-AE96-F2F4EFB4AEEF

P356

ATVBAHA.109.185918

P1433

Arteriosclerosis, Thrombosis, and Vascular Biology

P1476

Rapamycin inhibition of the Ak ...... in part by blocking S6Kinase.

@en

P2093

Eleanor J Manseau

http://www.w3.org/2001/XMLSchema#string

Harold F Dvorak

http://www.w3.org/2001/XMLSchema#string

Janice A Nagy

http://www.w3.org/2001/XMLSchema#string

Laura E Benjamin

http://www.w3.org/2001/XMLSchema#string

Qi Xue

http://www.w3.org/2001/XMLSchema#string

Thuy L Phung

http://www.w3.org/2001/XMLSchema#string

P2860

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex

Direct recruitment of CRK and GRB2 to VEGFR-3 induces proliferation, migration, and survival of endothelial cells through the activation of ERK, AKT, and JNK pathways

Identification of Sin1 as an essential TORC2 component required for complex formation and kinase activity

SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity

Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1

Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

Progression-free survival as endpoint in metastatic RCC?

VEGF-A and the induction of pathological angiogenesis.

P304

1172-1178

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1161/ATVBAHA.109.185918

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

29

http://www.w3.org/2001/XMLSchema#string

P577

2009-05-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19443844

http://www.w3.org/2001/XMLSchema#string

P932

2756965

http://www.w3.org/2001/XMLSchema#string